• Estrogen treatment in postmenopausal women requires

  2019-12-05

  

  Estrogen treatment in postmenopausal women requires combination with a progestogen in order to prevent endometrial stimulation. This is not necessary, however, with tibolone as progestogenic activity is associated with its Δ4-metabolite that is formed in the liver, as well as locally in the endometr

• Importantly our in vivo data fit to the in

  2019-12-05

  

  Importantly, our in vivo data fit to the in vitro data, further confirming the synergistic effect of XJD and gefitinib on the inhibition of lung cancer and the regulation of SP1, HOTAIR, and EP4 nfat levels. The doses of XJD used were based on our previous in vivo study (Zhao et al., 2016). We beli

• Artificial permutations have also been exploited by protein

  2019-12-05

  

  Artificial permutations have also been exploited by protein engineering to manipulate protein scaffolds, in order to improve catalytic activity, alter substrate or ligand binding affinity, reduce proteolytic susceptibility, increase stability, generate different aggregation states and improve fluore

• There are two types of DDRs DDR and DDR which

  2019-12-05

  

  There are two types of DDRs, DDR1 and DDR2, which are type I transmembrane RTKs characterized by an N-terminal extracellular discoidin domain containing a collagen binding site [8]. DDR1 expression is somewhat restricted to epithelial cells, while DDR2 is often expressed in cells of mesenchymal orig

• br Materials and methods br Results br

  2019-12-05

  

  Materials and methods Results Discussion Natural compounds and their derivatives have been investigated as candidates for the treatment of bone diseases and can also be the sources of nutraceutical agents and therapeutic agents [28]. Using peptides as therapeutic effects on bone-related dis

• On the opposite side sPLA X has also been

  2019-12-04

  

  On the opposite side, sPLA2-X has also been implicated in the pathology of cancer [167,168]. Human sPLA2-X induces lipid droplet formation in Ras-driven MDA-MB-231 triple-negative breast cancer AZD3264 synthesis and promotes their survival during nutrient stress. It acts through the products of its

• The ribosomal synthesis of D proteins

  2019-12-04

  

  The ribosomal synthesis of D-proteins is not currently feasible; the best effort undertaken so far was limited to the translational incorporation of two D-amino acids into the nascent protein chain by means of modified ribosomes (Dedkova et al., 2006). We therefore apply solid-phase peptide synthesi

• In LPS treated BV cells we

  2019-12-04

  

  In LPS-treated BV-2 cells, we found that the upregulated CysLT2R was translocated into the nucleus. The nuclear localization of CysLT2Rs in microglia has not been reported previously. It is known that CysLT1Rs in endothelial Phleomycin translocated to the nucleus in a ligand-independent manner after

• br Materials and methods br Results br Discussion In

  2019-12-04

  

  Materials and methods Results Discussion In this study, we developed a new CysLT1 and CysLT2 receptors-mediated Tacrolimus guinea pig model for screening both CysLT2 receptor and CysLT1/2 receptor antagonists. Unlike human CysLT2 receptors, which are equally stimulated by both LTC4 and LTD

• In conclusion our work provides

  2019-12-04

  

  In conclusion, our work provides the preclinical evidence showing the potent in vivo efficacy of AT7519 on chemoresistant cancer ppar agonist and its underlying mechanisms of action. Our work supports the biological rationale behind the clinical trials initiated with AT7519, particularly for the tre

• To better understand the mechanism of splicing in CLCN we

  2019-12-04

  

  To better understand the mechanism of splicing in CLCN1, we began by constructing a minigene spanning exons 5–7 of CLCN1, resulting in the synthetic CLCN1 (5–7) minigene. We also established a new assay using real-time reverse transcription (RT)-PCR, which can distinguish between splicing variants b

• Unexpectedly CRF receptor agonist and antagonist evoked simi

  2019-12-03

  

  Unexpectedly, CRF2 receptor agonist and antagonist evoked similar effects in the fall in tail skin temperature caused by restraint. However, Ucn3 reduced basal values of tail skin temperature, thus indicating that some degree of basal vasoconstriction caused by BNST treatment with Ucn3 may have con

• EPAC activation in VSMCs and ECs reverses

  2019-12-03

  

  EPAC activation in VSMCs and ECs reverses several processes involved in the development of in-stent restenosis. Of particular relevance is the ability of EPAC1 to induce SOCS3 gene expression, as SOCS3 exerts multiple protective effects in both cell types, while immunohistochemical studies have show

• br Disclosures br Acknowledgements This work

  2019-12-03

  

  Disclosures Acknowledgements This work was supported by the Natural Science Foundation of China (No. 81560587); the Fok Ying-Tong Education Foundation of China (No. 151107), the basic ability promotion project for young and middle-aged teachers in Universities in Guangxi (No. 2018KY1146) and t

• br ET Antagonist for the

  2019-12-03

  

  ET Antagonist for the Future: Macitentan and Atresentan Macitentan is an insurmountable antagonist, resulting from structure-activity studies to improve the efficacy and tolerability of bosentan, and gained approval in the United States in 2013 for the treatment of PAH. Actelion describes the com

16569 records 951/1105 page Previous Next First page 上5页 951952953954955 下5页 Last page